These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Leitersdorf E; Muratti EN; Eliav O; Peters TK Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807 [TBL] [Abstract][Full Text] [Related]
8. The relationships between anthropometric measurements, serum vitamin A and E concentrations and lipid profiles in overweight and obese subjects. Viroonudomphol D; Pongpaew P; Tungtrongchitr R; Changbumrung S; Tungtrongchitr A; Phonrat B; Vudhivai N; Schelp FP Asia Pac J Clin Nutr; 2003; 12(1):73-9. PubMed ID: 12737014 [TBL] [Abstract][Full Text] [Related]
9. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Devroey D; Velkeniers B; Duquet W; Betz W Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669 [TBL] [Abstract][Full Text] [Related]
11. Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia. Jacob BG; Richter WO; Schwandt P J Cardiovasc Pharmacol; 1993 Sep; 22(3):396-400. PubMed ID: 7504129 [TBL] [Abstract][Full Text] [Related]
12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
13. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858 [TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333 [TBL] [Abstract][Full Text] [Related]
16. Therapy of familial hypercholesterolemia in childhood: diet and cholestyramine resin for 24 to 36 months. Glueck CJ; Tsang RC; Fallat RW; Mellies M Pediatrics; 1977 Mar; 59(3):433-41. PubMed ID: 840563 [TBL] [Abstract][Full Text] [Related]
17. Vitamin A, retinol binding protein and lipids in type 1 diabetes mellitus. Baena RM; Campoy C; Bayés R; Blanca E; Fernández JM; Molina-Font JA Eur J Clin Nutr; 2002 Jan; 56(1):44-50. PubMed ID: 11840179 [TBL] [Abstract][Full Text] [Related]
18. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788 [TBL] [Abstract][Full Text] [Related]
19. Treatment of familial hypercholesterolemia with drugs in children. Stein EA Arteriosclerosis; 1989; 9(1 Suppl):I145-51. PubMed ID: 2912428 [TBL] [Abstract][Full Text] [Related]